Pulse Competitors
| PLSE Stock | USD 13.69 1.42 9.40% |
Pulse Biosciences vs ATAI Life Correlation
Very weak diversification
The correlation between Pulse Biosciences and ATAI is 0.57 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Pulse Biosciences and ATAI in the same portfolio, assuming nothing else is changed.
Moving against Pulse Stock
As of February 7, 2026, Return On Tangible Assets is expected to decline to -0.5. In addition to that, Return On Capital Employed is expected to decline to -0.55. At present, Pulse Biosciences' Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 144.2 M, whereas Non Current Assets Total are forecasted to decline to about 14.7 M.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Pulse Biosciences' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Pulse Biosciences Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Pulse Biosciences and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Pulse and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Pulse Biosciences does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Pulse Stock performing well and Pulse Biosciences Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Pulse Biosciences' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| STAA | 2.39 | (0.49) | 0.00 | 1.88 | 0.00 | 4.66 | 15.08 | |||
| LFMD | 3.72 | (1.07) | 0.00 | (0.22) | 0.00 | 8.55 | 28.11 | |||
| BBNX | 3.53 | (0.99) | 0.00 | (1.09) | 0.00 | 6.19 | 47.68 | |||
| KMTS | 2.47 | (0.08) | (0.02) | 0.01 | 3.86 | 4.59 | 20.54 | |||
| IMTX | 3.30 | 0.00 | 0.00 | 0.08 | 4.06 | 8.98 | 30.34 | |||
| OPK | 1.48 | (0.24) | 0.00 | (0.22) | 0.00 | 3.03 | 9.92 | |||
| DNTH | 2.97 | 0.69 | 0.19 | (14.29) | 2.66 | 8.95 | 23.32 | |||
| NKTR | 3.67 | (0.72) | 0.00 | (0.65) | 0.00 | 6.56 | 20.31 | |||
| NVCR | 2.66 | (0.41) | 0.00 | (0.10) | 0.00 | 4.95 | 20.87 | |||
| ATAI | 2.76 | (0.55) | 0.00 | (0.45) | 0.00 | 5.77 | 15.30 |
Cross Equities Net Income Analysis
Compare Pulse Biosciences and related stocks such as STAAR Surgical, LifeMD Inc, and Beta Bionics Common Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STAA | (3.8 M) | 1.3 M | (1.8 M) | 398 K | (8.4 M) | (6.5 M) | (12.1 M) | (2.1 M) | 5 M | 14 M | 5.9 M | 27.5 M | 39.7 M | 21.3 M | (20.2 M) | (23.2 M) | (22.1 M) |
| LFMD | (502.9 K) | (502.9 K) | (445.6 K) | (268.3 K) | (460.5 K) | (62 K) | (1.1 M) | (1.2 M) | (1.2 M) | (3.1 M) | (60.5 M) | (60.9 M) | (45.5 M) | (20.6 M) | (18.9 M) | (17 M) | (17.8 M) |
| BBNX | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (64.8 M) | (44.1 M) | (54.8 M) | (63 M) | (66.1 M) |
| KMTS | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (29.5 M) | (34.1 M) | (84.2 M) | (84.2 M) | (94.1 M) | (113.8 M) | (102.4 M) | (107.6 M) |
| IMTX | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.4 M) | (31.7 M) | (229.3 M) | (95.1 M) | 37.5 M | (97 M) | 15.2 M | 17.5 M | 18.4 M |
| OPK | (2.7 M) | (1.3 M) | (29 M) | (114.4 M) | (171.7 M) | (30 M) | (48.4 M) | (305.2 M) | (153 M) | (314.9 M) | 30.6 M | (30.1 M) | (328.4 M) | (188.9 M) | (53.2 M) | (47.9 M) | (50.3 M) |
| DNTH | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (9.4 M) | (35.5 M) | (57.5 M) | (76.8 M) | (74.9 M) | (13.1 M) | (28.5 M) | (43.6 M) | (85 M) | (76.5 M) | (72.6 M) |
| NKTR | (5.3 M) | (134 M) | (171.9 M) | (162 M) | (53.9 M) | (81.2 M) | (153.5 M) | (96.7 M) | 681.3 M | (440.7 M) | (444.4 M) | (523.8 M) | (368.2 M) | (276.1 M) | (119 M) | (107.1 M) | (112.4 M) |
| NVCR | (77.4 M) | (77.4 M) | (77.4 M) | (77.4 M) | (80.7 M) | (111.6 M) | (131.8 M) | (61.7 M) | (63.6 M) | (7.2 M) | 19.8 M | (58.4 M) | (92.5 M) | (207 M) | (168.6 M) | (151.8 M) | (144.2 M) |
| ATAI | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (14.1 M) | (169.8 M) | (167.8 M) | (152.4 M) | (40.2 M) | (149.3 M) | (134.3 M) | (141.1 M) |
Pulse Biosciences and related stocks such as STAAR Surgical, LifeMD Inc, and Beta Bionics Common Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Pulse Biosciences financial statement analysis. It represents the amount of money remaining after all of Pulse Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Pulse Biosciences Competitive Analysis
The better you understand Pulse Biosciences competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Pulse Biosciences' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Pulse Biosciences' competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Pulse Biosciences Competition Performance Charts
Five steps to successful analysis of Pulse Biosciences Competition
Pulse Biosciences' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Pulse Biosciences in relation to its competition. Pulse Biosciences' competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Pulse Biosciences in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Pulse Biosciences' competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Pulse Biosciences, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Pulse Biosciences position
In addition to having Pulse Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Banks Thematic Idea Now
Banks
Large and small money and credit banks and credit services. The Banks theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Banks Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Pulse Biosciences Correlation with its peers. For information on how to trade Pulse Stock refer to our How to Trade Pulse Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Will Health Care Equipment & Supplies sector continue expanding? Could Pulse diversify its offerings? Factors like these will boost the valuation of Pulse Biosciences. Anticipated expansion of Pulse directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Pulse Biosciences data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Pulse Biosciences using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Pulse Biosciences' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Pulse Biosciences' market price to deviate significantly from intrinsic value.
It's important to distinguish between Pulse Biosciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pulse Biosciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Pulse Biosciences' market price signifies the transaction level at which participants voluntarily complete trades.